(NASDAQ: TNGX) Tango Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.66%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 32.69%.
Tango Therapeutics's earnings in 2026 is -$207,998,000.On average, 15 Wall Street analysts forecast TNGX's earnings for 2026 to be -$244,642,414, with the lowest TNGX earnings forecast at -$260,723,709, and the highest TNGX earnings forecast at -$231,306,293. On average, 15 Wall Street analysts forecast TNGX's earnings for 2027 to be -$286,785,913, with the lowest TNGX earnings forecast at -$370,327,307, and the highest TNGX earnings forecast at -$220,630,618.
In 2028, TNGX is forecast to generate -$328,743,010 in earnings, with the lowest earnings forecast at -$438,414,390 and the highest earnings forecast at -$241,981,968.